在PCOS患者中对GLP-1进行人体测量,代谢和内分泌参数的系统审查
Salwa Bader1, Rahila Bhatti1,2, Bashair Mussa3
1University of Sharjah, Sharjah, United Arab Emirates.
Women's health (London, England)
|March 6, 2024
概括
类似葡萄糖-1受体激动剂有效降低体重,并改善多囊性卵巢综合征 (PCOS) 中的内分泌/代谢问题. 与甲福明的联合治疗显示,在PCOS患者中增加了体重减轻和代谢效益.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 代谢障碍 代谢障碍 代谢障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- 多囊性卵巢综合征 (PCOS) 是一种常见的内分泌疾病,影响生殖年龄的女性,其特点是高雄性,慢性无卵性和多囊性卵巢.
- 代谢异常,如胰岛素抵抗,肥胖,2型糖尿病,高血压和高脂血症在PCOS中普遍存在,影响整体健康.
- 减肥是PCOS的主要治疗方法,但药物干预可能是必要的,以实现最佳的血糖控制和内分泌改善.
结论:
- 类似葡萄糖-1受体激动剂在控制体重和改善PCOS妇女的精选内分泌和代谢参数方面是有效的.
- 结合GLP-1 RA和甲福明治疗对减肥和PCOS的代谢改善具有显著的优势,特别是在超重/肥胖个体中.
- 需要进一步的研究,以确定GLP-1 RA和甲福林联合治疗在PCOS治疗中的长期安全性和有效性.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
199
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
199
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Hormones Regulating Blood Glucose
3.3K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.3K
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Dipeptidyl Peptidase 4 Inhibitors
186
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
186


